Oppenheimer bullish on Opus Genetics, initiates with an Outperform

As previously reported, Oppenheimer analyst Andreas Argyrides initiated coverage of Opus Genetics (IRD) with an Outperform rating and $10 price target With encouraging initial signals of functional and structural improvements in a sentinel patient presented at Macular Society on February 27, the firm turns to full cohort 1 data mid-year to further derisk the OPGx-BEST1 program with positive results potentially sending shares up 50%-100% as BEST1 represents an over $1.5B market opportunity. OPGx-LCA5 is expected to start dosing in Phase 3 in the second half of 2026, with potential path to approval in 2029, Oppenheimer adds.